Welcome to our dedicated page for Ampio Pharma news (Ticker: AMPE), a resource for investors and traders seeking the latest updates and insights on Ampio Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ampio Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ampio Pharma's position in the market.
Ampio Pharmaceuticals (AMPE) reminds stockholders to vote on proposals ahead of its 2021 Annual Meeting set for August 14, 2021, at 9:00 a.m. (MT). Stockholders as of June 21, 2021, received proxy materials for the virtual event, which allows questions but restricts voting to recorded stockholders. Registration is required using a control number found in the proxy materials. The company appreciates stockholder support and will post a meeting replay online. Ampio focuses on immunology-based therapies for inflammatory conditions with ongoing development of its lead drug, Ampion.
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on immunology-based therapies, will host one-on-one investor meetings at two upcoming conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13-15, 2021, and the Cantor Fitzgerald Virtual Global Healthcare Conference will take place from September 27-30, 2021. Ampio's lead drug, Ampion™, which aims to treat prevalent inflammatory conditions, has a patent portfolio extending through 2037 and could secure 12-year FDA market exclusivity upon approval.
Ampio Pharmaceuticals (AMPE) reported its Q2 2021 financial results, highlighting significant advancements in its clinical trials. The company completed a Phase I trial for inhaled Ampion in COVID-19 patients, showing a 78% reduction in all-cause mortality. Following this success, Phase II trials have commenced, with enrollment expected to increase, including expansion to India. Cash and equivalents reached $20.5 million, up 18% from the previous year. The company's net loss was $3.6 million, a 30% increase from Q2 2020, while it anticipates enough liquidity to fund operations through Q4 2022.
Ampio Pharmaceuticals, a biopharmaceutical company focused on immunology therapies, announced its virtual presentation at the American College of Toxicology 42nd Annual Meeting from November 14 to 17, 2021. The poster titled 'Efficient Applied Toxicology during COVID-19' discusses results from the AP-014 Phase I trial of its inhaled drug, Ampion. The study revealed a 78% reduction in all-cause mortality in COVID-19 patients with respiratory distress compared to Standard of Care. Ampio is moving forward with a Phase II trial due to these promising results.
Ampio Pharmaceuticals (AMPE) announced a virtual presentation for their abstract titled "Significant Inhibition of the TLR7/CXCL10 Signaling Axis by LMWF5A" at the upcoming 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) on October 6-9, 2021. The presentation will explore Ampion™, currently in clinical trials for COVID-19 treatment, and its effects on cytokine release. Early data from the AP-014 Phase I trial indicates that inhaled Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% compared to standard care.
Ampio Pharmaceuticals (AMPE) announced its poster presentation titled "Inflammation and COVID Induced ARDS: Inhaled Ampion™ as a Therapeutic Option" at the 63rd annual Thomas L. Petty Aspen Lung Conference from September 20 to 23, 2021, in Aspen, Colorado. The poster showcases results from the AP-014 Phase I clinical trial, indicating that inhaled Ampion significantly reduced all-cause mortality in COVID-19 respiratory distress by 78%. Patients receiving Ampion had shorter hospital and ICU stays compared to the control group, and fewer needed Remdesivir treatment.
Ampio Pharmaceuticals (AMPE) will host a conference call on August 4, 2021, at 4:30 pm EDT to discuss its financial results for Q2 2021 and provide a corporate update. The call will be accessible domestically at 888-506-0062 and internationally at 973-528-0011, using conference ID 469825. Investors can also listen via the webcast available on Ampio's website. The company is focused on immunology-based therapies for inflammatory conditions, with its lead product, Ampion, backed by an extensive patent portfolio.
Ampio Pharmaceuticals (NYSE American: AMPE) announced the initiation of patient randomization and dosing in its multi-center AP-019 Phase II clinical trial for inhaled Ampion™ to treat respiratory distress from COVID-19. Following strong Phase I results showing a 78% reduction in all-cause mortality, the Phase II trial aims to confirm these outcomes. The company has also received FDA approval to expand the study to India amid rising COVID-19 cases. Ampion is positioned as an immunomodulatory agent to improve clinical outcomes for patients with severe respiratory issues.
Ampio Pharmaceuticals (AMPE) announced its anticipated inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 28, 2021. This milestone is expected to enhance the company's visibility within the investment community. The Russell indexes are fundamental benchmarks for investment strategies, with approximately $10.6 trillion in assets tied to them. Ampio focuses on immunology-based therapies, particularly its lead drug Ampion™, which holds a patent until 2035 and may qualify for 12-year FDA market exclusivity as a novel biologic.
Ampio Pharmaceuticals (AMPE) announced integrated data from four earlier clinical trials of Ampion for severe osteoarthritis of the knee (OAK). This analysis involved 585 patients and demonstrated significant pain reduction compared to saline at multiple intervals. The data highlights Ampion's efficacy, with reductions in pain of up to 38.1% at ten weeks. The FDA has agreed that one pivotal trial supports a future Biologics License Application (BLA). Despite COVID-19 delaying other trials, Ampio remains optimistic about upcoming results and aims to be the first novel OAK therapy in over 20 years.